Taiwan gives nod to Phase 2 trial of COVAXX’s UB-612 COVID-19 vaccine

American biotechnology company- COVAXX, a subsidiary of United Biomedical, Inc., has announced that the Taiwan Ministry of Health and Welfare has awarded conditional approval to commence Phase 2 clinical trial of UB-612, the firm’s coronavirus vaccine candidate.

Seemingly, COVAXX is developing the first multitope peptide-derived vaccines in the world to fight COVID-19, by using its commercially proven, high precision, scalable vaccine problem.

Notably, the Phase 2 clinical study is a placebo-controlled, multi-center, randomized, observer-blind study that further explores the safety, efficacy, immunogenicity, and tolerability of the vaccine candidate in three different cohorts namely-adolescents, adults, and seniors.

Citing reliable sources, the first subject of the study was enrolled in the last week of January 2021, with an aim of completing the enrollment and administration of the first doses of UB-612 among all the volunteers within a month. Additionally, the total number of subjects that have enrolled for the trial is 3,850.

Mei Mei Hu, CEO, COVAXX, was reportedly quoted stating that the coming steps in the development of the COVID-19 vaccine is an effective measure to fight the pandemic. The company’s multitope vaccine has showcased favorable results from the preclinical studies and Phase 1 trials, obtaining high titers of specific neutralizing antibodies along with T-cell responses against multiple viral structural proteins that were acknowledged by the patients who suffered from the novel coronavirus infection, she further added.    

Seemingly, COVAXX has inked a partnership with the University of Nebraska Medical Center to facilitate the clinical study in the United States, and with Diagnosticos da America SA- a leading Brazil-based clinical diagnostic firm to carry out Phase 2 and 3 trial and distribute vaccines across Brazil.

In addition to the above, COVAXX has also announced a partnership with a prominent Indian pharmaceutical company- Aurobindo Pharma, to aid the clinical testing, production, and distribution of UB-612 within India and to the UNICEF.

For the record, COVAXX’s vaccine is a temperature stable candidate that is stable at normal 2 to 8 degree Celsius and is not required to be stored at an ultra-low temperature cold chain. The American pharma is producing the first 100 million vaccine doses and will deliver more than 500 million doses this year.

Source Credit: https://www.prnewswire.com/news-releases/covaxx-announces-initiation-of-phase-2-clinical-trials-in-taiwan-of-ub-612-vaccine-candidate-against-covid-19-301220506.html